A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Statins improve pulmonary vascular remodeling and right ventricular hypertrophy in animal models of pulmonary arterial hypertension (PAH). However, clinical trials assessing the efficacy of statins in patients with PAH have reported mixed results. In this systematic review and meta‐analysis, we assess the efficacy of statins in patients with PAH. We included randomized controlled clinical trials (RCTs) that evaluated the efficacy of statins in patients with PAH. Primary outcomes were mortality and change in 6‐minute walk distance (6MWD). Data are presented as odds ratio (OR) and weighted mean difference (WMD), with 95% confidence intervals (CIs), for binary and continuous variables, respectively. We included 4 RCTs of high quality. The mean age of participants was 42 ± 13 years, and 70% were women. The statins used were simvastatin at 40–80 mg in two trials, atorvastatin 10 mg in one trial, and rosuvastatin 10 mg in the other. In the pooled‐data analysis, there was no statistically significant improvement in mortality (OR: 0.75 [95% CI: 0.32–1.74]), 6MWD (WMD: −9.27 [95% CI: −27.73 to 9.20]), or cardiac index (WMD: 0.11 [95% CI: −0.04 to 0.27]) with statin therapy when compared to placebo. There was no difference in adverse events leading to withdrawal of therapy between statin and placebo groups. These data suggest that statins are not beneficial in the treatment of PAH. There is a need for large, well‐conducted clinical trials assessing the effects of statins in patients with PAH. Future trials should include homogeneous patient populations and should be long‐term, event‐driven trials with combined morbidity and mortality end points.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Tuder, R. M., Archer, S. L., Dorfmüller, P., Erzurum, S. C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K. R., & Morrell, N. W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.025 · Cited by 585
Hoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., Gómez-Sánchez, M. A., Grimminger, F., Grünig, E., Hassoun, P. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000765 · Cited by 574
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation
Thenappan, T., Shah, S. J., Rich, S., Tian, L., Archer, S. L., & Gomberg-Maitland, M. (2010) · European Respiratory Journal · doi:10.1183/09031936.00072709 · Cited by 493
Self-citationAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
Humbert, M., Lau, E. M. T., Montani, D., Jaïs, X., Sitbon, O., & Simonneau, G. (2014) · Circulation · doi:10.1161/circulationaha.114.006974 · Cited by 342
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 333
The lipid and non-lipid effects of statins
Wierzbicki, A. S., Poston, R., & Ferro, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00055-x · Cited by 253
Nishimura, T., Vaszar, L. T., Faul, J. L., Zhao, G., Berry, G. J., Shi, L., Qiu, D., Benson, G., Pearl, R. G., & Kao, P. N. (2003) · Circulation · doi:10.1161/01.cir.0000087592.47401.37 · Cited by 251
Simvastatin Attenuates Smooth Muscle Neointimal Proliferation and Pulmonary Hypertension in Rats
Nishimura, T., Faul, J. L., Berry, G. J., Vaszar, L. T., Qiu, D., Pearl, R. G., & Kao, P. N. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200203-268oc · Cited by 191
Attenuation of chronic hypoxic pulmonary hypertension by simvastatin
Girgis, R. E., Li, D., Zhan, X., Garcia, J. G. N., Tuder, R. M., Hassoun, P. M., & Johns, R. A. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01097.2002 · Cited by 158
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Frost, A. E., Barst, R. J., Hoeper, M. M., Chang, H.-J., Frantz, R. P., Fukumoto, Y., Galié, N., Hassoun, P. M., Klose, H., Matsubara, H., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.05.025 · Cited by 148
Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT
Kawut, S. M., Bagiella, E., Lederer, D. J., Shimbo, D., Horn, E. M., Roberts, K. E., Hill, N. S., Barr, R. G., Rosenzweig, E. B., Post, W., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.015693 · Cited by 139
Simvastatin as a Treatment for Pulmonary Hypertension Trial
Wilkins, M. R., Ali, O., Bradlow, W., Wharton, J., Taegtmeyer, A., Rhodes, C. J., Ghofrani, H. A., Howard, L., Nihoyannopoulos, P., Mohiaddin, R. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009111-699oc · Cited by 135
Simvastatin Treatment of Pulmonary Hypertension*
Kao, P. N. (2005) · CHEST Journal · doi:10.1378/chest.127.4.1446 · Cited by 119
Lee, T.-M., Chen, C.-C., Shen, H.-N., & Chang, N.-C. (2009) · Clinical Science · doi:10.1042/cs20080241 · Cited by 104
McMurtry, M. S., Bonnet, S., Michelakis, E. D., Bonnet, S. B., Haromy, A., & Archer, S. L. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00310.2006 · Cited by 77
Atorvastatin in Pulmonary Arterial Hypertension (APATH) study
Zeng, W.-J., Xiong, C.-M., Zhao, L., Shan, G.-L., Liu, Z.-H., Xue, F., Gu, Q., Ni, X.-H., Zhao, Z.-H., Cheng, X.-S., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00149011 · Cited by 62
Sun, X., & Ku, D. D. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01112.2007 · Cited by 52
Seeger, H., Mueck, A. O., & Lippert, T. H. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38270 · Cited by 39
Moosavi, S. A. J., Raji, H., Faghankhani, M., Yazdani, R., & Esmaeili, M. (2013) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.8267 · Cited by 38
Barreto, A. C., Maeda, N. Y., Soares, R. P. S., Cícero, C., & Lopes, A. A. (2008) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2008000800003 · Cited by 33
Cited by
Wang, D., Uhrín, P., Mocan, A., Waltenberger, B., Breuss, J. M., Tewari, D., Mihaly‐Bison, J., Huminiecki, Ł., Starzyński, R. R., Tzvetkov, N. T., et al. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.006 · Cited by 116
Haber, N., Smith, E. R., Moscoe, E., Andrews, K., Audy, R., Bell, W., Brennan, A. T., Breskin, A., Kane, J. C., Karra, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196346 · Cited by 97
“An example in the UK [3] highlights the dangers of weak and poorly-reported evidence: An estimated 200,000 patients temporarily ceased taking statins–drugs with strong evidence for efficacy and safety for treating hypertension [4, 5]–after press outlets reported on two studies suggesting that the medication was associ…”
BackgroundHarbaum, L., Ghataorhe, P., Wharton, J., Jiménez, B., Howard, L., Gibbs, J. S. R., Nicholson, J. K., Rhodes, C. J., & Wilkins, M. R. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-212144 · Cited by 48
Shi, S., Gui, X., Ding, J., Yang, S., Xin, X., Xu, K., & Xiao, Y. (2022) · BioMed Research International · doi:10.1155/2022/1589660 · Cited by 20
Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases
Zhang, M., Qian, D., Xu, J., Yao, W., Ye, F., & Wang, C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.06 · Cited by 19
Metadata
- Authors
- Anand, V., Garg, S., Duval, S., & Thenappan, T.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Thenappan, Thenappan
- Venue
- Pulmonary Circulation
- Publisher
- Wiley
- Published
- 2016-09
- Volume
- 6
- Issue
- 3
- Pages
- 295-301
- ISSN
- 2045-8932 (ISSN-L)
- 2045-8940
- PMC
- PMC5019082
- OpenAlex
- W2346601422
- Semantic Scholar
- 9b3a591e2fa0bb2457af647231f89050ce27ce21
- Cited by
- 25
- References
- 30
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 7
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Pulmonary Circulation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association (15SDG25560048)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- statins, pulmonary arterial hypertension, simvastatin, atorvastatin, rosuvastatin, mortality, 6-minute walk distance, cardiac index, pulmonary vascular remodeling, right ventricular hypertrophy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.